GlassScriptPhysician profile
Kfir Shamir
NPI 1215142435
$16,790.17
in general payments reported to CMS, 2019-2025
32 companies · $2,560 in 2025
The $2,560 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,480 · 2020: $1,601 · 2021: $2,209 · 2022: $3,034 · 2023: $2,254 · 2024: $2,652 · 2025: $2,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,444 · Education: $22.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,443.72 |
| Education | $22.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,540.59 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $2,955.90 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $2,264.42 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,070.42 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Regeneron Healthcare Solutions, INC. | $980.25 | 2019-2025 | Dupixent |
| Pfizer INC. | $849.28 | 2019-2025 | |
| Optinose US, INC. | $782.88 | 2019-2025 | |
| Csl Behring | $713.64 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Kaleo, INC. | $614.59 | 2019-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $462.09 | 2019-2025 | |
| Genentech USA, INC. | $372.50 | 2019-2025 | Xolair |
| Grifols USA, LLC | $354.47 | 2019-2025 | Xembify |
| Abbvie INC. | $182.35 | 2022-2024 | Rinvoq |
| Teva Pharmaceuticals USA, INC. | $176.95 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $156.61 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $152.37 | 2022-2025 | Tezspire |
| Shire North American Group INC | $143.41 | 2019 | |
| Pharming Healthcare, INC. | $140.61 | 2019-2025 | Ruconest |
| Octapharma USA, INC. | $140.60 | 2020-2024 | Panzyga, Cutaquig, Octagam Immune Globulin (Human) |
| Genentech, INC. | $139.49 | 2025 | Xolair |
| Biocryst US Sales Co., LLC | $96.53 | 2022-2025 | Orladeyo |
| Phadia US INC. | $85.49 | 2019-2025 | Immunocap |
| Ars Pharmaceuticals Operations, INC. | $79.39 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $70.77 | 2019-2021 | |
| Ionis Pharmaceuticals, INC. | $63.41 | 2025 | Dawnzera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.46 | 2020-2021 | |
| Mylan Specialty L.P. | $32.97 | 2023 | Yupelri |
| Lilly USA, LLC | $30.40 | 2025 | Ebglyss |
| Horizon Therapeutics Plc | $24.06 | 2019 | |
| Galderma Laboratories, L.P. | $22.63 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $15.57 | 2024 | Ayvakit |
| Incyte Corporation | $15.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kfir Shamir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.